Trials / Terminated
TerminatedNCT04741542
Safety of SP-420 in the Treatment of Transfusional Iron Overload
Phase 1, Open-Label, Dose Escalation Study to Assess the Safety of SP-420 in the Treatment of Transfusional Iron Overload
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- The University of Texas Health Science Center at San Antonio · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study enrolls patients with myelodysplastic syndrome (MDS) and myelofibrosis (MFS), with transfusional iron overload and treats them with the investigational iron chelator, SP-420. SP-420 may be better tolerated and safer than commercially available iron chelators. Iron chelation therapy (ICT) has been shown to improve outcomes in iron overload, but adherence is poor due to problems related to ease of administration, tolerability, and safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SP-420 | This study aims to establish the safety of SP-420 administered orally three times per week (TIW). |
Timeline
- Start date
- 2021-03-09
- Primary completion
- 2024-01-10
- Completion
- 2024-01-10
- First posted
- 2021-02-05
- Last updated
- 2024-12-27
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04741542. Inclusion in this directory is not an endorsement.